IMMUCELL CORP /DE/(ICCC)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

IMMUCELL CORP /DE/ (ICCC) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ICCC at 51.3/100 on a 32-signal composite quality model, placing it at rank #1,548 of 2,962 stocks — the bottom half of the AI-ranked universe. ICCC scores in the top quartile across earnings quality (97.4), revenue growth (78.7). Areas of concern include revenue scale (5.3) and institutional flow (23.1), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), IMMUCELL CORP /DE/ reports quarterly revenue of $7.2M, net income of $1.8M, free cash flow of $2.3M. Top institutional holders of ICCC by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, MORGAN STANLEY, RENAISSANCE TECHNOLOGIES, based on the most recent SEC filings. ICCC trades on the Nasdaq exchange and files with the SEC under CIK 811641. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ICCC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for IMMUCELL CORP /DE/ directly from SEC EDGAR.